Collaborations

Overview

At Compugen, we are committed to discovering and developing groundbreaking therapies that unlock the power of the immune system to fight cancers.

To support us in the mission, we are continually seeking collaborations and strategic partnerships with leading biopharma companies worldwide to advance our early- and clinical-stage programs and bring transformational medicines that make a difference to patients.

If you would like to learn more about partnering with Compugen, please contact us at bd@cgen.com.

astra zeneca

 

 

 

About the Compugen-AstraZeneca license agreement

 
In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen’s monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. Compugen has received $40.5 million in upfront and milestone payments to date. Compugen is eligible to receive up to an aggregate milestone amount of $200 million in development and regulatory milestones for the first and second indications for the first product and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen’s monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Press Releases

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products

Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

gilead logo

About the Compugen-Gilead license agreement

In 2023 Compugen and Gilead entered into a license agreement, pursuant to which Gilead was granted exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including the COM503 drug candidate. Compugen was responsible for preclinical development and is the sponsor of the first- in-human Phase 1 trial evaluating the safety and tolerability of COM503. Gilead has the sole right to develop and commercialize COM503 thereafter. Gilead provided Compugen with a $60 million upfront payment and additional $30 million payment upon IND clearance of COM503. Compugen will be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of up to $848 million. Compugen will also be eligible to receive single- digit to low double-digit tiered royalties on worldwide net sales.

Press Releases

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program